“…In the crude model, the goodness fit was good so that the -2 log Likelihood was above 62 for each variable separately. However, in the adjusted model, it was about 44.57; *p < 0.05 oxygenation status that leads to immobility, non-invasive or mechanical ventilation requirement, ICU admission, and therefore, were prone to venous thromboembolic events [24,25]. Higher levels of absolute neutrophil count among those with on-admission thrombosis in comparison to the two other groups not only reinforced the theory about the rule of neutrophil hyperactivity and neutrophil traps in COVID-19-related hypercoagulability pathogenesis [26] but also ignites a hypothesis in terms of neutrophil count administration to make a decision for thromboprophylaxis administration in outpatient cases [27].…”
Introduction: Increasing evidence has declared a hypercoagulable state in the coronavirus 2019 infection (COVID-19), while the etiology has remained a question. For the first time, the current study has aimed to compare the contributors of thromboembolism among those whose primary manifestations of COVID-19 were thrombosis vs the patients with a thrombotic event during the period of hospitalization. Material and methods: This case-control study has been conducted on 267 COVID-19 patients, including 59, 48, and 160 ones with an on-admission, in-hospital, and without a thrombotic event, respectively. The events were defined as deep vein thrombosis (DVT), ischemic cerebrovascular accidents (CVA), pulmonary thromboembolism (PTE), or acute myocardial infarction (AMI). The demographic, physical examination, clinical and laboratory assessments of the groups were compared. Results: The DVT (OR: 5.18; 95% CI: 1.01–26.7), AMI (OR: 11.1; 95% CI: 2.36–52.3), and arterial thrombosis (OR: 5.93; 95% CI: 0.63–55.8) were significantly associated with an on-admission thrombosis compared to those who presented in-hospital events. Lower levels of oxygen saturation were the only significant predictor index inversely associated with on-admission thrombosis compared to those with an event during the hospital admission period. Conclusion: PTE development was the most common in-hospital thrombotic event, whereas other thromboembolism types were remarkably more often among cases with on-admission events. Oxygen saturation was the only predictor of premature thrombosis that was inversely associated with outpatient events.
“…In the crude model, the goodness fit was good so that the -2 log Likelihood was above 62 for each variable separately. However, in the adjusted model, it was about 44.57; *p < 0.05 oxygenation status that leads to immobility, non-invasive or mechanical ventilation requirement, ICU admission, and therefore, were prone to venous thromboembolic events [24,25]. Higher levels of absolute neutrophil count among those with on-admission thrombosis in comparison to the two other groups not only reinforced the theory about the rule of neutrophil hyperactivity and neutrophil traps in COVID-19-related hypercoagulability pathogenesis [26] but also ignites a hypothesis in terms of neutrophil count administration to make a decision for thromboprophylaxis administration in outpatient cases [27].…”
Introduction: Increasing evidence has declared a hypercoagulable state in the coronavirus 2019 infection (COVID-19), while the etiology has remained a question. For the first time, the current study has aimed to compare the contributors of thromboembolism among those whose primary manifestations of COVID-19 were thrombosis vs the patients with a thrombotic event during the period of hospitalization. Material and methods: This case-control study has been conducted on 267 COVID-19 patients, including 59, 48, and 160 ones with an on-admission, in-hospital, and without a thrombotic event, respectively. The events were defined as deep vein thrombosis (DVT), ischemic cerebrovascular accidents (CVA), pulmonary thromboembolism (PTE), or acute myocardial infarction (AMI). The demographic, physical examination, clinical and laboratory assessments of the groups were compared. Results: The DVT (OR: 5.18; 95% CI: 1.01–26.7), AMI (OR: 11.1; 95% CI: 2.36–52.3), and arterial thrombosis (OR: 5.93; 95% CI: 0.63–55.8) were significantly associated with an on-admission thrombosis compared to those who presented in-hospital events. Lower levels of oxygen saturation were the only significant predictor index inversely associated with on-admission thrombosis compared to those with an event during the hospital admission period. Conclusion: PTE development was the most common in-hospital thrombotic event, whereas other thromboembolism types were remarkably more often among cases with on-admission events. Oxygen saturation was the only predictor of premature thrombosis that was inversely associated with outpatient events.
“…A study performed by Suh et al found the PE incidence was higher in patients with COVID-19 than in patients with non–COVID-19 viral pneumonia who were admitted to the ICU, patients with acute respiratory distress syndrome, or patients with H1N1 influenza (swine flu) 38 . The presence of thromboembolic disease appears to be an added factor in worsened patient outcomes 39 . FIGURE 13 CTA chest in a 98 year old male with dyspnea in the setting of COVID-19.…”
Section: Pulmonary Embolism In Covid-19mentioning
confidence: 99%
“…Deciding whether or not to image a patient for a PE can be challenging given that the symptoms of PE and COVID overlap significantly 39 . Moreover, many patients infected with COVID-19 have an elevated D-dimer 37 .…”
Section: Approach To Evaluation Of Pulmonary Embolism In Covid Patientsmentioning
Synopsis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an easily transmissible coronavirus that emerged in late 2019 and has caused a global pandemic characterized by acute respiratory disease named Coronavirus Disease 2019 (COVID-19). Diagnostic imaging can be helpful as a complementary tool in supporting the diagnosis of COVID-19, and identifying alternative pathology. This article presents an overview of acute and post-acute imaging findings in COVID-19.
“…Another most important cause of respiratory distress and mortality is the presence of thromboembolic disease. Pulmonar y thromboembolism has been found to be a major factor [1] worsening the patient prognosis.…”
Introduction- COVID-19 disease has been associated with pro thrombotic state and endothelial damage resulting into
thromboembolic events ranging from venous thrombosis of lower limbs to pulmonary thrombo-embolism and
subsequently pulmonary infarctions.Computed tomographic pulmonary angiography (CTPA) was the standard of care
at our institute for evaluation of patients with suspected pulmonary embolism. It plays a key role in its confirmatory
diagnosis,defining its extent and thereby helping in better management.
Materials and Methods-A Retrospective study was done in Sri Aurobindo Medical College and Post graduate Institute,
Indore,Madhya Pradesh,India and was approved by the hospital ethical committee.The study was done on 300 COVID19 patients with clinically suspected pulmonary thromboembolism who underwent CTPA between the months of
January 2021 and October 2021.The scans were analysed by experienced radiologists.
Results- Through our study we found that approx.13.7% patients had pulmonary thromboembolism and it was seen in
patients with moderate to severe lung involvement.
Conclusion- Through this study we have tried to assess the presence pulmonary thromboembolism using CTPA and
have also tried to establish its relationship with percentage of lung involvement on CT.
Aims and Objectives - To assess for the presence of acute pulmonary thromboembolism in COVID 19 patients using
CTPA and to establish its relationship with severity of lung involvement on CT in a single institute in Central India during
a span of six months.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
